ISM8969
AssetAlso HT-001
Oral brain-penetrant NLRP3 inflammasome inhibitor for chronic neuroinflammation
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- NLRP3
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Obese adult participants at risk of cardiovascular disease
Phase 1, Recruiting, NCT07581431, clinicaltrials.gov, 16 Oct 2026
Parkinson's disease
Preclinical, insilico.com, 8 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials1
- Evidence for its targets2
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.